{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:08Z","timestamp":1792718348672,"version":"4.5.0"},"reference-count":106,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Potassium\u2010competitive acid blockers (P\u2010CABs) are a novel group of acid\u2010suppressing medicines for the management of acid\u2010related disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To review published clinical pharmacology studies and clinical trials of P\u2010CABs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive literature search including Medline (PubMed), EMBASE, Web of Science and the Cochrane Library from inception until November 2020, for studies of the clinical pharmacology of P\u2010CABs and relevant clinical trials of those that are currently licensed or in development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most publications concerned vonoprazan, which forms the bulk of this review. It is currently licensed in some Asian and South American countries and is being developed for North America. In clinically relevant doses, P\u2010CABs have produced more rapid and profound suppression of intragastric acidity than proton pump inhibitors (PPIs). Vonoprazan was non\u2010inferior to lansoprazole in healing erosive oesophagitis (2 randomised controlled trials [RCTs] in 1137 subjects) and superior in maintaining remission (1 RCT; 607 subjects). In 2 RCTs (1120 total subjects), both vonoprazan and tegoprazan were non\u2010inferior to lansoprazole for healing peptic ulcers. Three RCTs and numerous non\u2010randomised studies have compared vonoprazan\u2010based and PPI\u2010based regimens for\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      infection; vonoprazan\u2010based triple or dual regimens have been highly effective.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>P\u2010CABs have some potential advantages over PPIs. To date, most research has been conducted in Asia; results of clinical trials that are underway in the United States and Europe are anticipated in 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.16295","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T02:30:15Z","timestamp":1693535415000},"page":"794-809","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Review article: potassium\u2010competitive acid blockers for the treatment of acid\u2010related disorders"],"prefix":"10.1111","volume":"53","author":[{"given":"Yousef","family":"Abdel\u2010Aziz","sequence":"first","affiliation":[{"name":"Division of Gastroenterology University of Tennessee College of Medicine Memphis TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Metz","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology University of Pennsylvania Perelman School of Medicine Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0987-0662","authenticated-orcid":false,"given":"Colin W.","family":"Howden","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology University of Tennessee College of Medicine Memphis TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.39"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.35.040195.001425"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000200917"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1990.tb00445.x"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.9.1120"},{"key":"e_1_2_14_7_1","first-page":"481","article-title":"pH and Hp\u2013gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism","volume":"88","author":"Hunt RH","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2007.00508.x"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0368-z"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.08.010"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.05.005"},{"key":"e_1_2_14_12_1","first-page":"1163","article-title":"Vonoprazan: a novel potassium\u2010competitive acid blocker","volume":"73","author":"Sugano K","year":"2015","journal-title":"Nihon Rinsho"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S228352"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1346087"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100040c"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.07.002"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm7010063"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2019.27.2.80"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15438"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.18"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17745776"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0326-7"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13325"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13121"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i14.1550"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13461"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13331"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17705329"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15062"},{"key":"e_1_2_14_30_1","unstructured":"Pharmaceuticals P.A phase 3 randomized double\u2010blind two phase multicenter study to evaluate the efficacy and safety of vonoprazan 20\u00a0mg compared to lansoprazole 30\u00a0mg for healing in patients with erosive esophagitis and to evaluate the efficacy and safety of vonoprazan (10\u00a0mg and 20\u00a0mg) compared to lansoprazole 15\u00a0mg for the maintenance of healing in patients with healed erosive esophagitis.2019.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04124926"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.145581"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000101"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2016.12.001"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506152"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-018-00654-9"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000485795"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2017.07.004"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.167"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01587-5"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13876"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2020.02.012"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i32.5108"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.2.225"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000331138"},{"key":"e_1_2_14_45_1","first-page":"678","article-title":"Basal protrusion of ulcers induced by endoscopic submucosal dissection (ESD) during treatment with proton pump inhibitors, and the suppressive effects of polaprezinc","volume":"57","author":"Inaba T","year":"2010","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1067-4380"},{"key":"e_1_2_14_47_1","first-page":"245","article-title":"Effect of vonoprazan on delayed bleeding after endoscopic submucosal dissection for gastric neoplasia among antithrombotic drug users: a single\u2010center, single\u2010arm prospective observational case control study","volume":"74","author":"Yamamoto S","year":"2020","journal-title":"Acta Med Okayama"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1159\/000507807"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1146-18"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1487-6"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1615092"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4948-0"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/den.12857"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13747"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019357"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12813"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015860"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01055"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.911886"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001204"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314852"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314010"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0455-2"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319954"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.11-94"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01709-4"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1159\/000502287"},{"key":"e_1_2_14_68_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000485097","article-title":"Vonoprazan, a novel potassium\u2010competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second\u2010generation proton pump inhibitors for Helicobacter pylori eradication therapy","volume":"9","author":"Ozaki H","year":"2018","journal-title":"Digestion"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4385161"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7833"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9781212"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14130"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311304"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312028"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1159\/000504939"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12438"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2019802"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12374"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14456"},{"key":"e_1_2_14_80_1","doi-asserted-by":"crossref","first-page":"e12719","DOI":"10.1111\/hel.12719","article-title":"Efficacy and safety of a new rifabutin\u2010based triple therapy with vonoprazan for refractory Helicobacter pylori infection: a prospective single\u2010arm study","author":"Hirata Y","year":"2020","journal-title":"Helicobacter"},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2233-18"},{"key":"e_1_2_14_82_1","first-page":"550","article-title":"Usefulness of vonoprazan, a potassium ion\u2010competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest","volume":"7","author":"Amada S","year":"2016","journal-title":"Pharmacol Ther"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.10.003"},{"key":"e_1_2_14_84_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i4.668"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1159\/000490889"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2018.03.009"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2016.1203505"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13959"},{"key":"e_1_2_14_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12495"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00316"},{"key":"e_1_2_14_91_1","unstructured":"Pharmaceuticals P.A phase 3 randomized multicenter study to evaluate the efficacy and safety of open\u2010label dual therapy with oral vonoprazan 20 mg or double\u2010blind triple therapy with oral vonoprazan 20 mg compared to double\u2010blind triple therapy with oral lansoprazole 30 mg daily in patients withHelicobacter pyloriinfection.2019."},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1676722"},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/jat.3607"},{"key":"e_1_2_14_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.863"},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0488-6"},{"key":"e_1_2_14_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0521-7"},{"key":"e_1_2_14_97_1","doi-asserted-by":"publisher","DOI":"10.1159\/000484217"},{"key":"e_1_2_14_98_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S144149"},{"key":"e_1_2_14_99_1","first-page":"Tu1362","article-title":"2\u2010year interim analysis results of VISION TRIAL: a randomized, open\u2010label study to evaluate the long\u2010term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis","volume":"158","author":"Akiyama JUN","year":"2020","journal-title":"Gastroenterology"},{"key":"e_1_2_14_100_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000591"},{"key":"e_1_2_14_101_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000590"},{"key":"e_1_2_14_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16151"},{"key":"e_1_2_14_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16198"},{"key":"e_1_2_14_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16121"},{"key":"e_1_2_14_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15185"},{"key":"e_1_2_14_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15865"},{"key":"e_1_2_14_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16131"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.16295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T15:02:49Z","timestamp":1703084569000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.16295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/apt.16295"],"URL":"https:\/\/doi.org\/10.1111\/apt.16295","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"2020-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}